From Casetext: Smarter Legal Research

United States v. Yoo

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON AT SEATTLE
Nov 18, 2020
CR17-75TSZ (W.D. Wash. Nov. 18, 2020)

Opinion

CR17-75TSZ

11-18-2020

UNITED STATES OF AMERICA, Plaintiff, v. CHRIS YOUNG YOO, Defendant.


ORDER

THIS MATTER comes before the Court on Defendant's Motion for Compassionate Release, docket no. 53. Having reviewed all papers filed in support of, and in opposition to, the motion, the Court enters the following order DENYING the motion. Background

Defendant was resentenced on December 28, 2018, to 97 months in the custody of the United States Bureau of Prisons ("BOP"). See Amended Judgment (docket no. 40). Defendant is currently incarcerated at FCI Sheridan and has a projected release date of July 10, 2024. Defendant might also be eligible for additional early release credits if he successfully completes the RDAP program. He anticipates placement in a half-way house in the summer of 2023. Def.'s Mot. at 2 (docket 53). Upon release, defendant will be on supervised release for three (3) years. He now seeks immediate release on the grounds that his medical conditions (obesity, latent tuberculosis, hypertension, hyperlipidemia (elevated cholesterol levels), and pre-diabetes) increase the possibility of acute illness or death from Coronavirus Disease 2019 ("COVID-19"). Discussion

A sentence is generally considered final and may not be altered except in limited circumstances. See 18 U.S.C. § 3582(b); see also Dillon v . United States , 560 U.S. 817, 824 (2010). Prior to 2018, a modification for reasons other than a post-conviction reduction in the applicable sentencing range could be made only upon a motion brought by the Director of BOP. See United States v . Rodriguez , 451 F. Supp. 3d 392 (E.D. Penn. 2020). Congress has since enacted the First Step Act of 2018, which permits a defendant, after exhausting administrative remedies, to directly request a reduction in the term of incarceration. See 18 U.S.C. § 3582(c)(1)(A). The First Step Act did not, however, amend the two statutorily enumerated grounds for compassionate release, namely (i) the existence of "extraordinary and compelling reasons" supporting a reduction; or (ii) the satisfaction of certain criteria for a defendant sentenced to life imprisonment under 18 U.S.C. § 3559(c), which does not apply in this case. See id . at §§ 3582(c)(1)(A)(i) & (ii); Riley v . United States , 2020 WL 1819838 at *6-7 (W.D. Wash. Apr. 10, 2020). In addition, any compassionate release must be consistent with (i) the sentencing factors set forth in 18 U.S.C. § 3553(a), and (ii) the applicable policy statement issued by the United States Sentencing Commission ("Commission"). See 18 U.S.C. § 3582(c)(1)(A).

The parties agree that defendant has met the prerequisite of exhaustion. --------

As adopted in 1984, the statute did not define "extraordinary and compelling reasons," but rather delegated to the United States Sentencing Commission the task of describing the grounds for a sentence reduction that would qualify as "extraordinary and compelling." See 28 U.S.C. § 994(t); see also Pub. L. No. 98-473, §§ 212(a)(2) & 217(a), 98 Stat. 1837, 1998 & 2019 (1984). The Commission promulgated United States Sentencing Guideline ("USSG") § 1B1.13, the application notes of which describe three categories of potentially "extraordinary and compelling reasons," namely medical condition, age, and family circumstances, see USSG § 1B1.13 cmt. n.1(A)-(C), as well as a "catch-all" provision, id . cmt. n.1(D), which "opens the door" to considering factors other than those specifically enumerated, see United States v . McPherson , 454 F. Supp. 3d 1049 (W.D. Wash. 2020). The comments to USSG § 1B1.13 do not constrain the Court in evaluating whether the grounds for release articulated by defendant are "extraordinary and compelling," but they do provide helpful guidance. See United States v . Locke , 2020 WL 3101016 at *4 (W.D. Wash. June 11, 2020).

1. Obesity

Defendant relies on an e-mail to his counsel, dated July 30, 2020, in which he states that he weighs 220 pounds, and has a BMI of 30, which places him in the "obese" range. Exs. A & B to Def.'s Mot. (docket nos. 53-1 & 53-2). No medical record documents this claim. In contrast, the Government notes that, as of July 1, 2020, defendant weighed 208 pounds, which makes him "overweight," not "obese." See Exs. B & D to Def.'s Mot. (docket no. 55 at 2).. Even assuming a recent weight gain to 220 pounds, which "flirts with obesity," Def.'s Reply at 4 (docket 65), it would not justify a release at this time. Defendant's alleged weight gain presents only a slight risk, which remains in large part within his control, and is no different than the weight gain many people have experienced as a result of limitations on their activity during this COVID-19 crisis.

2. Latent Tuberculosis

Defendant was diagnosed (via a purified protein derivative ("PPD") test) with a non-symptomatic or latent tuberculosis ("TB") infection, and he refused prophylactic treatment on April 20, 2018, and again on July 1, 2020. Ex. D to Def.'s Mot. (docket no. 55 at 2, 15).. Notably, however, defendant requested treatment shortly before filing this motion for release. Latent TB is controlled with a short course of treatment that is safe and effective. See https://www.cdc.gov/tb/topic/treatment/ltbi.htm. This condition is not an extraordinary and compelling reason for release. United States v . Quintero , 2020 WL 3639936 at *3 (N.D. Cal. July 6, 2020).

Defendant's reliance on United States v . Atwi , 455 F. Supp. 3d 426 (E.D. Mich. 2020), is misplaced. That decision involved a defendant serving only a four-month sentence who had symptoms of "coughing up blood" and would require a 12-week course of antibiotic treatment for tuberculosis, which exceeded the period remaining on defendant's term of incarceration. Defendant has not exhibited any TB symptoms, and most courts since Atwi have refused to grant a release for latent TB. See , e.g., United States v . Heredia, 2020 WL 3971617 at *2 (N.D. Cal. July 14, 2020) (neither latent nor active tuberculosis is a condition placing a person at a heightened COVID-19 risk).

3. Hypertension

Defendant's medical records do not support his claim of Stage 2 hypertension. On July 1, 2020, his blood pressure was 125/80, see Ex. D to Def.'s Mot. (docket no. 55 at 2), which places him below the range for even Stage 1 systolic hypertension, and at the bottom of the range for diastolic hypertension. See https://www.cdc.gov/bloodpresure/facts.htm. Moreover, the CDC has identified hypertension as only a "possible," and not an actual, COVID-19 risk factor. Numerous courts have denied release for individuals who suffer from this condition. See , e .g., United States v . Carter , 2020 WL 4194014 (S.D. Ga. July 21, 2020). Defendant's alleged hypertension does not support his release.

4. Hyperlipidemia

Defendant's medical records indicate that his hyperlipidemia is well controlled with medication. See Ex. D to Def.'s Mot. (docket no. 55 at 1, 7). In December 2019, defendant's triglycerides were 125 mg/dL, (<150 is normal), HDL cholesterol was 59 mg/dL (within the normal range of 40-60), LDL cholesterol was 146 mg/dL (<130 is normal), and cholesterol/HDL ratio was 3.9 (within the normal range of 0-4). Id . (docket no. 55 at 19). In August 2020, defendant's blood chemistry results showed him holding fairly steady, with HDL cholesterol at 60 mg/dL and a cholesterol/HDL ratio of 4.1, only slightly higher than normal. Ex. 3 to Gov't Resp. (docket no. 62 at 12). Defendant has offered no basis for believing that his cholesterol levels pose any COVID-19 related risk for him.

5. Pre-Diabetes

Defendant's recent test results indicate a risk of diabetes. Pre-diabetes, however, is not itself a risk factor for COVID-19. Rather, it merely means defendant is at risk of developing the risk factor of diabetes. See United States v . Hazam, 2020 WL 3265349 at *2 (C.D. Ill. June 17, 2020).

6. Conditions at FCI Sheridan

Defendant also relies on the existence of COVID-19 in the BOP system and at FCI Sheridan where he is housed. Although FCI Sheridan had four (4) active COVID-19 cases on September 17, 2020, when the Government filed its response, as of the date of this Order, FCI Sheridan has no inmates who have tested positive for COVID-19. See https://www.bop.gov/coronavirus/ (visited Nov. 18, 2020); see also Keller Decl., Exs. 4 & 5 to Gov't Resp. (docket nos. 60-3 & 60-4) (describing the successful efforts at FCI Sheridan to control the novel coronavirus).

7. Combination of Factors

The various conditions on which defendant relies do not individually or in the aggregate constitute the "extraordinary and compelling reasons" necessary for a compassionate release. Defendant has failed to meet his burden of establishing a basis for a compassionate release. Thus, the Court need not address whether any compassionate release would be consistent with the factors set forth in 18 U.S.C. § 3553(a). Conclusion

For the foregoing reasons, the Court ORDERS:

(1) Defendant's Motion for Compassionate Release, docket no. 53, is DENIED; and

(2) The Clerk is directed to send a copy of this Order to all counsel of record.

IT IS SO ORDERED.

Dated this 18th day of November, 2020.

/s/_________

Thomas S. Zilly

United States District Judge


Summaries of

United States v. Yoo

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON AT SEATTLE
Nov 18, 2020
CR17-75TSZ (W.D. Wash. Nov. 18, 2020)
Case details for

United States v. Yoo

Case Details

Full title:UNITED STATES OF AMERICA, Plaintiff, v. CHRIS YOUNG YOO, Defendant.

Court:UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON AT SEATTLE

Date published: Nov 18, 2020

Citations

CR17-75TSZ (W.D. Wash. Nov. 18, 2020)

Citing Cases

United States v. Washington

“[M]ost courts since Atwi have refused to grant release for latent TB.” United States v. Yoo, No.…